| Name | Ensartinib hydrochloride |
| Description | Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both wild-type ALK and ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. |
| In vitro | Ensartinib potently inhibits both wild-type ALK and all evaluated ALK variants (C1156Y, F1174, G1202R, L1196M, S1206R, and T1151 mutants) with in vitro IC50s of <4 nM. Besides ALK, ensartinib also potently inhibits GOPC-ROS1, TPM3-TRKA, and TRKC with an IC50 of <1 nM, and inhibits EphA1, EphA2, EphB1 and c-MET with an IC50 of 1-10 nM[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 33 mg/mL (52.02 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 2 mg/mL (3.15 mM), Sonication is recommeded.
|
| Keywords | X-396 Dihydrochloride | X396 Dihydrochloride | X-396 | X396 | X 396 Dihydrochloride | X 396 | Trkreceptor | TRKC | Trk receptor | TPM3-TRKA | Inhibitor | inhibit | HGFR | GOPC-ROS1 | Ensartinib hydrochloride | Ensartinib Hydrochloride | Ensartinib Dihydrochloride | Ensartinib | c-Met/HGFR | cMet/HGFR | c-Met | cMet | Cluster of differentiation 246 | CD246 | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK variants | ALK tyrosine kinase receptor | ALK |
| Inhibitors Related | Entrectinib | DMH-1 | Larotrectinib sulfate | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | SP600125 | Amitriptyline hydrochloride | Ceritinib | Diosmetin | GW 441756 | Cabozantinib S-malate | A 83-01 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
